• Consensus Rating: Buy
  • Consensus Price Target: $16.00
  • Forecasted Upside: 365.12%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.44
▲ +0.16 (4.88%)

This chart shows the closing price for ACIU by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AC Immune Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACIU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACIU

Analyst Price Target is $16.00
▲ +365.12% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for AC Immune in the last 3 months. The average price target is $16.00, with a high forecast of $16.00 and a low forecast of $16.00. The average price target represents a 365.12% upside from the last price of $3.44.

This chart shows the closing price for ACIU for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in AC Immune. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$16.00Low
8/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$16.00Low
4/19/2023HC WainwrightReiterated RatingBuy$16.00Low
3/17/2023HC WainwrightReiterated RatingBuy$16.00Low
7/11/2022SVB LeerinkLower TargetOutperform$15.00 ➝ $10.00N/A
6/17/2022HC WainwrightReiterated RatingBuy$16.00Low
3/23/2022HC WainwrightReiterated RatingBuy$16.00Low
12/20/2021SVB LeerinkLower TargetOutperform$17.00 ➝ $15.00Medium
11/12/2021SVB LeerinkReiterated RatingBuy$17.00High
10/17/2021SVB LeerinkReiterated RatingOutperformLow
8/8/2021SVB LeerinkReiterated RatingBuy$17.00Low
3/24/2021HC WainwrightBoost TargetBuy$11.00 ➝ $16.00High
9/24/2020HC WainwrightReiterated RatingBuy$11.00High
12/10/2019HC WainwrightReiterated RatingBuy$8.00 ➝ $11.00Medium
7/12/2019HC WainwrightSet TargetBuy$8.00Low
(Data available from 2/24/2019 forward)

News Sentiment Rating

0.94 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2023
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2023
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2023
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2023
  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2023
  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 8 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2024

Current Sentiment

  • 8 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

AC Immune logo
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Read More

Today's Range

Now: $3.44
Low: $3.10
High: $3.49

50 Day Range

MA: $3.84
Low: $2.66
High: $5.00

52 Week Range

Now: $3.44
Low: $1.78
High: $5.14

Volume

113,570 shs

Average Volume

137,045 shs

Market Capitalization

$290.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02

Frequently Asked Questions

What sell-side analysts currently cover shares of AC Immune?

The following Wall Street research analysts have issued research reports on AC Immune in the last year: HC Wainwright, and StockNews.com.
View the latest analyst ratings for ACIU.

What is the current price target for AC Immune?

1 Wall Street analysts have set twelve-month price targets for AC Immune in the last year. Their average twelve-month price target is $16.00, suggesting a possible upside of 365.1%. HC Wainwright has the highest price target set, predicting ACIU will reach $16.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $16.00 for AC Immune in the next year.
View the latest price targets for ACIU.

What is the current consensus analyst rating for AC Immune?

AC Immune currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACIU will outperform the market and that investors should add to their positions of AC Immune.
View the latest ratings for ACIU.

What other companies compete with AC Immune?

How do I contact AC Immune's investor relations team?

AC Immune's physical mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company's listed phone number is (121) 345-9121 and its investor relations email address is [email protected]. The official website for AC Immune is www.acimmune.com. Learn More about contacing AC Immune investor relations.